Pages that link to "Q28140278"
Jump to navigation
Jump to search
The following pages link to Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein (Q28140278):
Displaying 50 items.
- Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies (Q24561905) (← links)
- Filamentous bacteriophage fd as an antigen delivery system in vaccination (Q26864071) (← links)
- Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp41 (Q27312171) (← links)
- Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates (Q27489500) (← links)
- Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion (Q27641682) (← links)
- Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications (Q27657377) (← links)
- Structure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing Epitope (Q27675260) (← links)
- Structure and Immunogenicity of a Peptide Vaccine, Including the Complete HIV-1 gp41 2F5 Epitope (Q27681352) (← links)
- Recognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicity (Q28484544) (← links)
- Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies (Q29619015) (← links)
- Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. (Q31016954) (← links)
- Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. (Q31016969) (← links)
- Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing (Q33392865) (← links)
- Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope (Q33417195) (← links)
- Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region (Q33508799) (← links)
- Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution (Q33778466) (← links)
- Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant (Q33812812) (← links)
- Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity (Q33826951) (← links)
- Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development (Q33842152) (← links)
- HIV-1 gp41 Core with Exposed Membrane-Proximal External Region Inducing Broad HIV-1 Neutralizing Antibodies (Q33869882) (← links)
- Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines (Q33916676) (← links)
- Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. (Q34204047) (← links)
- Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies (Q34324992) (← links)
- Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope (Q34348303) (← links)
- Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody (Q34353296) (← links)
- Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion (Q34359035) (← links)
- A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1 (Q34396912) (← links)
- Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5 (Q34434753) (← links)
- Survey of the year 2000 commercial optical biosensor literature (Q34464911) (← links)
- Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. (Q34543052) (← links)
- A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. (Q34552313) (← links)
- In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth (Q34937404) (← links)
- Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterolo (Q35024202) (← links)
- Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides. (Q35034311) (← links)
- Spying on HIV with SPR. (Q35089512) (← links)
- Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles (Q35704086) (← links)
- Identifying epitopes of HIV-1 that induce protective antibodies (Q35708836) (← links)
- In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. (Q38637769) (← links)
- Targeting antibody responses to the membrane proximal external region of the envelope glycoprotein of human immunodeficiency virus (Q35998559) (← links)
- Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens (Q36138144) (← links)
- Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region (Q36372534) (← links)
- Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design (Q36447540) (← links)
- The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design (Q36497712) (← links)
- The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. (Q36509423) (← links)
- Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit (Q36544143) (← links)
- Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. (Q36600380) (← links)
- Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens (Q36747750) (← links)
- The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5. (Q36898696) (← links)
- Development of prophylactic vaccines against HIV-1. (Q37042563) (← links)
- An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene (Q37064315) (← links)